Physician profile
Sarah E Cusworth
NPI 1306251525
$2,186.89
in general payments reported to CMS, 2019-2025
26 companies · $21.63 in 2025
The $21.63 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $262 · 2021: $661 · 2022: $415 · 2023: $476 · 2024: $233 · 2025: $21.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.38 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.97 | 2019-2024 | Liletta, Orilissa, Lo Loestrin Fe |
| Coopersurgical, INC. | $205.38 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $202.66 | 2021-2023 | Phexxi |
| Meditrina | $128.47 | 2021-2023 | |
| Organon LLC | $118.49 | 2022-2025 | Nexplanon |
| Avion Pharmaceuticals | $82.63 | 2020-2022 | |
| Astellas Pharma US INC | $82.47 | 2023-2024 | Veozah |
| Agile Therapeutics, INC. | $74.38 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $66.74 | 2020-2023 | Slynd |
| Merck Sharp & Dohme LLC | $65.05 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $60.31 | 2021-2023 | |
| Hologic Sales and Service, LLC | $55.16 | 2023-2024 | Third Wave, Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $47.99 | 2023-2024 | Myfembree |
| Millicent US INC | $40.41 | 2024 | Femring |
| Biohaven Pharmaceuticals, INC. | $38.68 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $38.43 | 2021-2022 | |
| Lupin INC. | $36.12 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.82 | 2020-2022 | |
| Minerva Surgical, INC | $29.58 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $28.12 | 2019 | |
| Shield Therapeutics INC | $18.70 | 2023 | Accrufer |
| Mission Pharmacal Company | $17.46 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.21 | 2019 | |
| Allergan, INC. | $15.59 | 2020 | |
| Axonics, INC. | $13.13 | 2023 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cusworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.